Stifel analyst Annabel Samimy says that despite "positive news flow," shares of Evolus "remain depressed by overhangs." The analyst believes this presents a "strong buying opportunity" at current share levels. With all metrics "pointing in the right direction", Evolus has "strong tailwinds" continuing into 2020 and its sales momentum should continue, Samimy tells investors in a research note. With its singularity in focus on the toxin launch, Jeuveau is on target to be among the top five aesthetic product launches, reaching a number three position in less than six months, adds the analyst. Samimy maintains a Buy rating on Evolus with a $33 price target. The stock in morning trading is up 33c to $11.50.